Moderna and IAVI to cooperate on developing vaccines
Moderna will offer its messenger ribonucleic acid mRNA technology, while IAVI will bring its expertise in research and development to the project.
Based in La Jolla, California, IAVI is a global non-profit scientific research organization dedicated to addressing urgent, unmet global health challenges, including human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS).
Some 95 million people were infected with diseases like HIV, AIDS, and bacterial gastroenteritis in 2020 alone, with an estimated 4 million dying, according to the company.
“We are excited to partner with IAVI to leverage the power of mRNA and extend our commitment to global health across multiple diseases. Moderna’s mRNA platform, with its speed, scale, and flexibility, is uniquely suited to tackle current and emerging pathogens," said Stéphane Bancel, CEO of Moderna. “With our mRNA technology and IAVI’s discovery and development expertise, together we have an opportunity to address persistent global health threats.”
BY SARAH CHEA [email@example.com]